Compare LSBK & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | CTMX |
|---|---|---|
| Founded | 1891 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 596.2M |
| IPO Year | 2006 | 2015 |
| Metric | LSBK | CTMX |
|---|---|---|
| Price | $15.01 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 17.4K | ★ 2.1M |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 105.28 | 50.22 |
| EPS | ★ 1.21 | 0.24 |
| Revenue | $27,774,000.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $12.47 | $17.49 |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $11.50 | $0.40 |
| 52 Week High | $16.95 | $4.62 |
| Indicator | LSBK | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 57.94 |
| Support Level | $14.82 | $3.78 |
| Resistance Level | $15.19 | $4.25 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 81.63 | 79.85 |
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.